Medherant, a clinical-stage company developing treatments using a novel transdermal drug delivery technology, has reported positive results from its phase 1 study of the TEPI Patch, a testosterone therapy designed to support women during menopause.
David Haddleton, Chief Scientific Officer at Medherant and Professor in the Department of Chemistry, University of Warwick, UK said: “The success of this initial trial paves the way for our upcoming multiple-dose study which will start dosing before the end of the year.”
Founded in 2014 as a University of Warwick spin-out, Medherant reported that its first clinical trial, conducted at Hammersmith Medicines Research (HMR), evaluated a pilot formulation of its optimised TEPI Patch. The study found that testosterone levels in post-menopausal participants returned to pre-menopausal ranges following treatment, demonstrating the patch’s potential to restore hormonal balance.
The TEPI Patch uses a proprietary adhesive system, which Medherant reported is well-tolerated by patients while remaining flexible and comfortable. The company has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) and the Research Ethics Committee for its Clinical Trial Application for a subsequent phase 1 multiple-dose pharmacokinetic study, which will investigate the TEPI Patch in treating additional menopausal symptoms.
“These latest results represent another major step in the development of the testosterone TEPI Patch to address a significant condition faced by many post-menopausal women,” said Karolina Afors, Medherant’s Medical Director.